Blurbs

Analysts Are Bullish on These Healthcare Stocks: Syros Pharmaceuticals (SYRS), Motus Gi Holdings (MOTS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (SYRSResearch Report), Motus Gi Holdings (MOTSResearch Report) and TransCode Therapeutics (RNAZResearch Report) with bullish sentiments.

Syros Pharmaceuticals (SYRS)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Syros Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Monday at $3.66, close to its 52-week low of $3.52.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.4% and a 35.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $30.75, which is a 686.4% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $60.00 price target.

See the top stocks recommended by analysts >>

Motus Gi Holdings (MOTS)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Motus Gi Holdings, with a price target of $10.00. The company’s shares closed last Monday at $1.87, close to its 52-week low of $1.53.

According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -28.1% and a 24.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, EyePoint Pharmaceuticals, and Aslan Pharmaceuticals.

Currently, the analyst consensus on Motus Gi Holdings is a Moderate Buy with an average price target of $8.00, implying a 344.4% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.

TransCode Therapeutics (RNAZ)

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TransCode Therapeutics today and set a price target of $6.00. The company’s shares closed last Monday at $0.51, close to its 52-week low of $0.45.

According to TipRanks.com, Bodnar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.8% and a 37.3% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Context Therapeutics, and SQZ Biotechnologies.

TransCode Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SYRS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More